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OBJECTIVES We sought to quantify the impact of adding an intravenous loading dose to a subcutaneous
regimen of enoxaparin in patients with an acute coronary syndrome (ACS).
BACKGROUND It is unclear whether an intravenous (IV) loading dose of enoxaparin should be added to a
subcutaneous (SQ) regimen in patients with ACS.
METHODS Patients admitted with ACS were randomized to IVSQ (n  14) or SQ alone (n  11)
enoxaparin treatment. Coagulation markers were measured at nine time points during the
first 24 h of treatment.
RESULTS The IVSQ therapy immediately resulted in therapeutic anti-Xa levels, which remained
significantly higher for 6 h compared with SQ alone, without reaching excessively high levels.
A rapid decrease of plasma prothrombin fragments 12 (F12) levels was observed as soon
as 5 min after the IV injection (33% lower; p  0.007), and these levels remained lower up
to 2 h after the start of treatment compared with SQ alone. The ex vivo thrombin generation
time was maximally prolonged at 5 min post-injection in the IVSQ group and remained
significantly prolonged up to 6 h post-injection compared with SQ alone. The tissue factor
pathway inhibitor plasma activity was immediately increased by 194% with IVSQ, whereas
the maximum increase with SQ alone was 47% at 3 h.
CONCLUSIONS Therapeutic plasma levels of enoxaparin are achieved significantly earlier by an IVSQ
regimen compared with SQ alone, without leading to unacceptably high levels. As the risk of
thrombotic complications is greatest early after admission, the observed differences in
antithrombotic effects may translate into a clinical benefit. However, this remains to be
established. (J Am Coll Cardiol 2003;42:424–7) © 2003 by the American College of
Cardiology Foundation
Low-molecular-weight heparins (LMWH) are now rou-
tinely used in the initial treatment of patients admitted with
acute coronary syndromes (ACS). However, there is no
uniformity regarding the initiation of LMWH, both in
clinical trials and clinical practice. In several trials (1–3),
treatment was initiated by subcutaneous (SQ) injection on
hospital admission. In contrast, other trials (4,5) used a
combined regimen, with an intravenous (IV) loading dose
followed by SQ administration. An IV loading dose may
benefit these patients, as the highest event rates are observed
early after admission. However, this combined regimen
results in higher initial plasma drug levels, potentially
increasing the risk of bleeding. No studies have compared
these regimens.
Therefore, we quantified the impact on the coagulation
system in patients admitted with ACS in a randomized
comparison of these two regimens.
METHODS
Patient selection and treatment. Patients admitted to the
Coronary Care Unit at the Academic Medical Center
(Amsterdam, The Netherlands) with a diagnosis of unstable
angina or non–Q-wave myocardial infarction were eligible.
Patients using anticoagulants, including heparin and warfa-
rin, or antiplatelet agents other than aspirin (i.e., clopi-
dogrel, nonsteroidal anti-inflammatory drugs) were not
included.
After written informed consent was obtained, patients
were randomized to 40 mg IV enoxaparin combined with
SQ enoxaparin or SQ enoxaparin alone. In the combined
group, SQ enoxaparin was administered within 2 min after
the IV dose.
Based on a standard dose of 1 mg/kg, the following SQ
dose of enoxaparin was administered twice daily: 60 mg if
the body weight was 70 kg, 80 mg for weight between 70
and 90 kg, and 100 mg if 90 kg. Aspirin was dosed at 100
mg once daily.
The study was approved by the Institutional Review
Board of the Academic Medical Center in Amsterdam.
Blood sampling. Nine blood samples were obtained during
the first day of admission: before administration of enox-
aparin, at 5 min, and 1, 2, 3, 4, 6, 8, and 24 h after the start
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of enoxaparin. Blood samples were obtained through an IV
catheter, which was distal to other systems and not used for
medication. The IV catheter was only flushed with 0.9%
saline, performed just before and after blood sampling. At
each blood sampling, the first 2 ml blood was discarded, and
9 ml blood was collected in citrated Vacutainer tubes (4.5 ml
sodium-citrate 0.105 molair 0.5 ml per 4.5 ml blood).
Immediately after sampling, the blood was centrifuged at
2,200 g for 20 min at 6°C. Plasma was separated and filled
out in cryocups and frozen at 80°C until analysis was
performed. These procedures were completed within 1 h
after blood sampling.
Assays. Anticoagulation levels were determined by an anti-
factor Xa (anti-Xa) determination with a chromogenic assay
(coated heparin, Chromogenix, Mo¨lndal, Sweden) cali-
brated against enoxaparin.
To measure in vivo thrombin generation, prothrombin
fragment 1  2 (F12) plasma concentrations were deter-
mined by sandwich-type enzyme-linked immunosorbent
assay (Dade-Behring, Marburg, Germany). Additionally,
the thrombin generation time (TGT) was determined,
reflecting ex vivo thrombin formation using calcium and
recombinant human tissue factor (Dade, Innovin). Results
were measured spectrophotometrically and expressed as
T1⁄2 max (time to reach the mid-point of clear to maximum
turbid density).
Tissue factor pathway inhibitor activity (TFPI), a natural
anticoagulant, was quantified by a sandwich-type enzyme-
linked immunosorbent assay from Behring (Marburg, Ger-
many).
Statistical analysis. Differences between the groups per
time point were identified using an independent samples t
test.
Differences between the groups in total thrombin gener-
ation (TGT, F12) and TFPI plasma levels over the time
period 0 to 8 h were identified using an independent
samples t test over the calculated area under the curve
(AUC) between time points 0 h and 8 h.
Differences within a group between time points were
compared using a paired samples t test.
RESULTS
Baseline characteristics. Of the 25 patients randomized,
14 received IVSQ enoxaparin (IVSQ group) and 11
received SQ enoxaparin alone (SQ group). The baseline
characteristics of the two groups were comparable (Table 1).
During the first 24 h of treatment, no bleeding compli-
cations occurred. Six patients in the IVSQ group and two
patients in the SQ group had recurrent anginal symptoms;
of these eight patients, only three had accompanying isch-
emic electrocardiographic changes (one IVSQ and two
SQ patients). In both groups, one patient underwent coro-
nary angiography, and one revascularization was performed
(IVSQ group).
Anticoagulation levels. Within 5 min after IV injection of
enoxaparin, the mean anti-Xa levels rose from 0 to 1.25
U/ml (Fig. 1). During the following hours, the levels
gradually decreased to 0.63 U/ml after 8 h. In contrast, 5
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ACS  acute coronary syndrome
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AUC  area under the curve
F12  prothrombin fragments 12
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LMWH  low-molecular-weight heparin
SQ  subcutaneous
TFPI  tissue factor pathway inhibitor
TGT  thrombin generation time
Table 1. Patient Characteristics
SQ Alone
Group
(n  11)
IVSQ
Group
(n  14) p Value
Females 4 (36) 5 (36) NS
Age (yrs) 63  13 63  10 NS
BMI (kg/m2) 28  4 27  4 NS
Weight (kg) 84  11 79  15 NS
Diabetes 2 (18) 1 (7) NS
Smoking 0 4 (29) NS
Hyperlipidemia 4 (36) 6 (43) NS
Hypertension 6 (55) 6 (43) NS
History of coronary disease
Stable angina 6 (55) 4 (29) NS
Unstable angina 2 (18) 4 (29) NS
Myocardial infarction 3 (27) 2 (14) NS
Angioplasty 2 (18) 3 (21) NS
CABG 2 (18) 1 (7) NS
Aspirin use on admission 9 (82) 7 (50) NS
ST-segment elevation and/or
depression on admission
4 (36) 7 (50) NS
Data are presented as the number (%) of patients or mean value  SD.
BMI  body mass index; CABG  coronary artery bypass graft surgery; IV 
intravenous; NS  not significant; SQ  subcutaneous.
Figure 1. Anti-factor Xa (anti-Xa) levels during the first 24 h of treatment
with subcutaneous (SQ) alone (solid circles) or intravenous SQ (open
squares) enoxaparin. Data are presented as the mean value  SEM.
Dotted lines represent the lower and upper therapeutic range (0.5 and 1.0
U/ml, respectively). Significant differences (p  0.05) using the t test
between the two groups are marked with an asterisk.
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min after SQ alone administration, the anti-Xa levels were
still undetectable, increasing to 0.30 U/ml after 1 h, and
remained significantly lower up to 6 h compared with the
IVSQ group. The AUC between time points 0 and 8 h
was significantly higher in the IVSQ group compared
with the SQ alone group (p  0.0005). Anti-Xa levels at
steady-state (24 h after baseline) were comparable between
both groups (0.90 U/ml).
In vitro thrombin generation. Higher initial anti-Xa lev-
els were reflected in the TGT (Fig. 2). A slow increase in
TGT was observed after SQ alone injection, rising from
170 s at baseline to a maximum of 738 s at 6 h. Intravenous
loading resulted in an immediate increase of TGT to
2,000 s 5 min after injection, which remained significantly
higher during the first 6 h compared with SQ alone group.
This delay in thrombin generation was reflected in a
significant higher AUC in the IVSQ group compared
with the SQ alone group (p  0.0005).
In vivo thrombin generation. Intravenous bolus injection
resulted in a rapid decrease of F12, with significantly lower
levels compared with baseline levels, as soon as 5 min
post-injection (0.76 nmol/l; p  0.0005), which further
decreased in the first 24 h to 0.58 nmol/l (Fig. 3). In the SQ
alone group, 2 h after administration, F12 levels were
significantly lower than baseline (p  0.01) and reached the
lowest level of 0.71 nmol/l at 24 h. Significantly lower F12
levels between in the IVSQ group compared with the SQ
alone group were observed at the 5-min, 1-h and 2-h time
points. The AUC between time points 0 and 8 h was
nonsignificantly reduced by 19% in the IVSQ group
compared with the SQ alone group (p  0.2).
In vivo natural anticoagulants. Intravenous enoxaparin
resulted in an immediate increase of plasma TFPI, tripling
the mean plasma activity from 80% to 294% (Fig. 4).
Subcutaneous alone administration showed a modest in-
crease of plasma TFPI activity from 79% to a maximum of
126% at 3 h. During the first 2 h, TFPI was significantly
different between the treatment groups. Six hours after the
start of treatment, both groups had returned to baseline
TFPI levels. A 68% higher AUC in the IVSQ group was
observed (p  0.1).
DISCUSSION
Our study demonstrates that combined IV and SQ enox-
aparin administration, compared with SQ alone enoxaparin,
in the initial treatment of patients with ACS results in a
more rapid inhibition of the coagulation system. This is
reflected by an immediate decrease of plasma levels of the in
vivo thrombin generation marker F12 and of ex vivo
prolongation of TGT. Intravenous initiation of enoxaparin
treatment immediately resulted in therapeutic anticoagula-
tion levels, with anti-Xa levels of 1.25 U/ml within 5 min
Figure 2. Thrombin generation time (TGT) during the first 24 h of
treatment with subcutaneous (SQ) alone (solid circles) or intravenous
SQ (open squares) enoxaparin. Data are presented as the mean value 
SEM. Significant differences (p  0.05) using the t test between the two
groups are marked with an asterisk.
Figure 3. Levels of prothrombin fragments 1  2 (F12) during the first
24 h of treatment with subcutaneous (SQ) alone (solid circles) or
intravenous SQ (open squares) enoxaparin. Data are presented as the
mean value  SEM. Significant differences (p  0.05) using the t test
between the two groups are marked with an asterisk.
Figure 4. Activity of tissue factor pathway inhibitor (TFPI) during the first
24 h of treatment with subcutaneous (SQ) alone (solid circles) or
intravenous SQ (open squares) enoxaparin. Data are presented as the
mean value  SEM. Significant differences (p  0.05) using the t test
between the two groups are marked with an asterisk.
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after administration. Furthermore, an immediate release of
TFPI was observed, tripling TFPI plasma activity. This
rapidly induced anticoagulant effect remained significantly
greater up to 6 h after the start of treatment, compared with
the SQ alone enoxaparin regimen.
Whether the reduction in thrombin generation during
the first hour of ACS treatment results in a reduction of
ischemic events cannot be derived from our study. A
retrospective comparison of trials using SQ LMWH (1–3)
with those using IVSQ LMWH (4,5) is not reliable
because of the differences in patients and methods. The
Clopidogrel in Unstable Angina to Prevent Recurrent
Ischemic Events study demonstrated that antithrombotic
treatment may have an impact on clinical events as early as
four hours after initiation of treatment (6). Consequently,
we postulate that adequate anticoagulant drug levels are
desirable as early as possible.
An immediate and significant increase of TFPI activity
caused by IV enoxaparin was observed. This rapid release
could be of benefit, especially in these ACS patients.
Coronary plaque rupture exposes subendothelial tissue fac-
tor to the circulation (7,8), which is a strong activator of the
coagulation system and local thrombus formation. The
TFPI binds to the tissue factor-factor VII complex (TF-
VII) and inhibits the procoagulant properties of TF-VIIa.
Also, TFPI has been shown to reduce tissue factor activity,
particularly in human atherosclerotic plaques (9). We ob-
served no depletion of TFPI activity in the IVSQ group as
compared with the SQ alone group.
A potential disadvantage of a combined IV and SQ
regimen is an increased risk of bleeding complications. We
observed maximum mean peak anti-Xa levels of 1.25 U/ml
in the IVSQ group 5 min after treatment start. These
levels are comparable with those observed during steady-
state SQ alone treatment in healthy volunteers (1.2 U/ml)
(10) and ACS patients (1.0 U/ml [range 0.9 to 1.2]) (11).
Because the therapeutic range of enoxaparin is 0.5 to 1.0
U/ml (10), patients given an IV loading dose are below this
upper limit within 1 h after administration (Fig. 1). It is
therefore unlikely that maximum anti-Xa levels after 40 mg
IV enoxaparin will induce an unacceptable increased risk of
bleeding complications. This is supported by a comparison
of the data from the Thrombolysis In Myocardial
Infarction-11B (TIMI-11B) and Efficacy Safety Subcuta-
neous Enoxaparin in Non–Q-wave Coronary Events (ES-
SENCE) studies, using 30 mg IVSQ and SQ alone
enoxaparin regimens, respectively (3,4). The incidence of
minor bleeding during the first 24 h of treatment in the
IVSQ patients was 1.8% versus 2.1% in the SQ alone
patients. Major bleedings occurred in 0.26% versus 0.31% of
the patients, respectively. Both this indirect comparison and
our data do not suggest that an initial IV loading dose of
LMWH is associated with an excessive risk of bleeding that
might offset the benefit of achieving therapeutic drug levels
early.
Conclusions. Therapeutic drug levels were achieved signif-
icantly earlier with combined IVSQ treatment compared
with SQ alone treatment. This resulted in a 2 to 6 h earlier
reduction of in vivo thrombin generation marker F12
levels, a delay in TGT, and an early threefold increase of
plasma TFPI activity, compared with SQ alone enoxaparin.
The combined IVSQ regimen did not result in unaccept-
ably high anticoagulation levels. Clearly, this does not rule
out a potential increase in the risk of bleeding complica-
tions. Our results suggest that a combined IV plus SQ start
of LMWH administration in the treatment of ACS patients
may result in a clinical benefit, compared with a regimen of
SQ alone. However, this clinical benefit remains to be
determined.
Reprint requests and correspondence: Dr. Nick R. Bijsterveld,
Department of Cardiology, Room F3-241, Academic Medical
Center, Meibergdreef 9, 1105 AZ, P.O. Box 22660, 1100 DD,
Amsterdam, The Netherlands. E-mail: n.r.bijsterveld@amc.uva.nl.
REFERENCES
1. The FRISC Investigators. Low-molecular-weight heparin during
instability in coronary artery disease: FRagmin during InStability in
Coronary artery disease study. Lancet 1996;347:561–8.
2. Klein W, Buchwald A, Hillis SE, et al. Comparison of low-molecular-
weight heparin with unfractionated heparin acutely and with placebo
for 6 weeks in the management of unstable coronary artery disease:
FRagmin In unstable Coronary artery disease (FRIC) study. Circula-
tion 1997;96:61–8.
3. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-
molecular-weight heparin with unfractionated heparin for unstable
coronary artery disease (ESSENCE). N Engl J Med 1997;337:447–52.
4. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents
death and cardiac ischemic events in unstable angina/non–Q-wave
myocardial infarction (TIMI 11B). Circulation 1999;100:1593–601.
5. The FRAXIS Study Group. Comparison of two treatment durations
(6 days and 14 days) of a low molecular weight heparin with a 6-day
treatment of unfractionated heparin in the initial management of
unstable angina or non–Q-wave myocardial infarction: FRAXIS
(FRAXiparine in Ischaemic Syndrome). Eur Heart J 1999;20:1553–
62.
6. The CURE Investigators. Effects of clopidogrel in addition to aspirin
in patients with acute coronary syndromes without ST-segment
elevation. N Engl J Med 2001;345:494–502.
7. Marmur JD, Thiruvikraman SV, Fyfe BS, et al. Identification of active
tissue factor in human coronary atheroma. Circulation 1996;94:1226–
32.
8. Toschi V, Gallo R, Lettino M, et al. Tissue factor modulates the
thrombogenicity of human atherosclerotic plaques. Circulation 1997;
95:594–9.
9. Caplice NM, Mueske CS, Kleppe LS, et al. Presence of tissue factor
pathway inhibitor in human atherosclerotic plaques is associated with
reduced tissue factor activity. Circulation 1998;98:1051–7.
10. Enoxaparin. Investigator Brochure Lovenox, Clexane, Klexane (enox-
aparin sodium). December 18, 2001.
11. The TIMI 11A Investigators. Dose-ranging trial of enoxaparin for
unstable angina: results of TIMI 11A. J Am Coll Cardiol 1997;29:
1474–82.
427JACC Vol. 42, No. 3, 2003 Bijsterveld et al.
August 6, 2003:424–7 Loading Dose of Enoxaparin in ACS Patients
